Precision BioSciences, Inc. has commenced dosing in the Phase 1/2 FUNCTION-DMD study with the first patient receiving PBGENE-DMD at Arkansas Children’s Hospital.
Published
Signal category
Research & Knowledge
Quote
“Precision BioSciences has commenced dosing in the Phase 1/2 FUNCTION‑DMD study, with the first patient receiving PBGENE‑DMD at Arkansas Children’s Hospital.”
— Precision BioSciences, Inc. team
Company
Precision BioSciences, Inc.
Dedicated to Improving Life.
- Industry
- Biotechnology Research
- Location
- Durham, US
- Company size
- 98 employees
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
Founded 2006